Home About us Contact
|
Home About us Contact | ||
|
|
||
Anticancer Drug Delivery (anticancer + drug_delivery)
Selected AbstractsAnticancer Drug Delivery: Doxorubicin-Conjugated Immuno-Nanoparticles for Intracellular Anticancer Drug Delivery (Adv. Funct.ADVANCED FUNCTIONAL MATERIALS, Issue 11 2009Mater. Self-assembled polymeric nanoparticles of the amphiphilic copolymer poly(TMCC-co-LA)-g-PEG-furan can couple both anti-HER2 antibodies and chemotherapeutic doxorubicin (DOX) on their surfaces, report Molly Shoichet and co-workers on page 1689. This novel strategy selectively delivers DOX to the cell nucleus of HER2-overexpressing breast cancer cells while maintaining the pharmaceutical toxicity of DOX, paving the way to targeted drug delivery in breast cancer treatment. [source] Doxorubicin-Conjugated Immuno-Nanoparticles for Intracellular Anticancer Drug DeliveryADVANCED FUNCTIONAL MATERIALS, Issue 11 2009Meng Shi Abstract A polymeric nanoparticle comprised of surface furan groups is used to bind, by Diels,Alder (DA) coupling chemistry, both targeting anti-human epidermal growth factor receptor 2 (anti-HER2) antibodies and chemotherapeutic doxorubicin (DOX) for targeted, intracellular delivery of DOX. In this new approach for delivery, where both chemotherapeutic and targeting ligand are attached, for the first time, to the surface of the delivery vehicle, the nuclear localization of DOX in HER2-overexpressing breast cancer SKBR-3 cells is demonstrated, as determined by confocal laser scanning microscopy. Flow cytometric analysis shows that the conjugated DOX maintains its biological function and induces similar apoptotic progression in SKBR-3 cells as free DOX. The viable cell counts of SKBR-3 cancer cells following incubation with different nanoparticle formulations demonstrates that the combined DOX and anti-HER2 nanoparticle is more efficacious than the nanoparticle formulation with either DOX or anti-HER2 alone. While free DOX shows similar cytotoxicity against both cancerous SKBR-3 cells and healthy HMEC-1 cells, the combined DOX-anti-HER2 nanoparticle is significantly more cytotoxic against SKBR-3 cells than HMEC-1 cells, suggesting the benefit of nanoparticle-conjugated DOX for cell type-specific targeting. The DOX-conjugated immuno-nanoparticle represents an entirely new method for localized co-delivery of chemotherapeutics and antibodies. [source] Entering and Lighting Up Nuclei Using Hollow Chitosan,Gold Hybrid NanospheresADVANCED MATERIALS, Issue 36 2009Yong Hu Functional hollow CS,PAA,Au-hybrid nanospheres are prepared in aqueous solution via a one-pot route. These hollow hybrid nanospheres can not only act as drug carriers for intracellular and intranuclear drug delivery, but also act as a contrast agent in cancer-cell imaging, and light up the nucleus. This results in a nanosphere that can execute tumor-cell imaging and anticancer drug delivery at the same time. [source] Core/shell pH-sensitive micelles self-assembled from cholesterol conjugated oligopeptides for anticancer drug deliveryAICHE JOURNAL, Issue 7 2010Xin Dong Guo Abstract A doxorubicin (DOX) delivery system of pH-sensitive micelles self-assembled from cholesterol conjugated His5Arg10 (HR15-Chol) and His10Arg10 (HR20-Chol) has been described in this article. The amphiphilic molecules have low critical micelle concentrations of 17.8 and 28.2 ,g/mL for HR15-Chol and HR20-Chol, respectively, even at a low pH of 5.0. The pH-sensitive histidine segment of the polypeptide block is insoluble at pH 7.4 but becomes positively charged and soluble via protonation at pH lower than 6.0. The size and zeta potential of DOX-loaded micelles increases with the decrease in pH. Coarse-grained simulations were performed to verify the structure of DOX-loaded micelles and pH sensitivity of HR15/20-Chol. The in vitro DOX release from the micelles is significantly accelerated by decreasing pH from 7.4 to 5.0. Furthermore, DOX release from the micelles is controlled by a Fickian diffusion mechanism. These micelles have great potential applications in delivering hydrophobic anticancer drugs for improved cancer therapy. © 2009 American Institute of Chemical Engineers AIChE J, 2010 [source] | ||||||||||